Sugi Predict

Sugi Predict / Compounds / SCHEMBL3719136

SCHEMBL3719136

SCHEMBL3719136

CC(C)Oc1ccc(O)cc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 1/20 0.41
▸ ALOX5 P09917 1/20 0.38
▸ PTGS2 P35354 1/20 0.38
▸ CA12 O43570 2/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ CA7 P43166 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ CA14 Q9ULX7 2/20 0.37
▸ MAOB P27338 1/20 0.36
▸ LMNA P02545 3/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ ATM Q13315 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ CSNK2A1 P68400 2/20 0.36
▸ RORC P51449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677324 0.84 MAOB (0.41) XDHALOX5PTGS2CA12CA1
SCHEMBL17175977 0.80 MEN1 (0.35) ALOX5PTGS2MAOBLMNASMN1; SMN2
SCHEMBL9259271 0.79 MAPK1 (0.58) XDHLMNASMN1; SMN2ATMALDH1A1
SCHEMBL19433124 0.79 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL28373416 0.78 ALDH1A1 (0.44) XDHLMNASMN1; SMN2ATMALDH1A1
SCHEMBL16956140 0.78 CYP1A2 (0.46) XDHLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL3716834 0.78 HTR2B (0.42) CA12CA1CA2CA7CA9
SCHEMBL23813103 0.77 XDH (0.39) XDHLMNASMN1; SMN2ATMALDH1A1
SCHEMBL3719650 0.77 CSNK2A1 (0.45) XDHLMNASMN1; SMN2ATMALDH1A1
SCHEMBL16956910 0.77 ALDH1A1 (0.44) XDHLMNAALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
EP-3844151-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-08-23 — — EP disclosed
CN-109843856-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2023-05-02 — — CN disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11548888-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2023-01-10 — — US disclosed
EP-4087573-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2022-11-16 — — EP disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
EP-2794563-B1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2017-02-22 — — EP disclosed
CN-104011021-B heterocyclic derivatives and their use as prostaglandin D2 receptor modulators 埃科特莱茵药品有限公司 2016-08-24 — — CN disclosed
US-9255090-B2 Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-09 — — US disclosed
US-20150344518-A1 ESTROGEN RECEPTOR IMAGING AGENTS UNITED STATES DEPARTMENT OF ENERGY 2015-12-03 — — US disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 — — US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 — — EP disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 — — WO disclosed
WO-2010127208-A1 INHIBITORS OF ACETYL-COA CARBOXYLASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 XDH 1359/4885ALOX5 33/4885PTGS2 16/4885
US-11548888-B2 KRas G12C inhibitors KRAS, NRAS, HRAS XDH 4517/4885ALOX5 4441/4885PTGS2 3014/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS XDH 4517/4885ALOX5 4441/4885PTGS2 3014/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS XDH 4517/4885ALOX5 4441/4885PTGS2 3014/4885
US-20150344518-A1 ESTROGEN RECEPTOR IMAGING AGENTS ESR1, GPER1, ESR2 XDH 3601/4885ALOX5 2604/4885PTGS2 1524/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS XDH 4517/4885ALOX5 4441/4885PTGS2 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.